Invex Therapeutics (ASX:IXC) Stock Based Compensation: A$0.00 Mil (TTM As of Dec. 2025)


What is Invex Therapeutics Stock Based Compensation?

Invex Therapeutics ASX:IXC Stock Based Compensation is A$0.00 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Invex Therapeutics's Stock Based Compensation for the six months ended in Dec. 2025 was A$0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Invex Therapeutics Stock Based Compensation Related Terms

Invex Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Stock Based Compensation Chart

Invex Therapeutics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Invex Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

What does a Stock Based Compensation of A$0.00 Mil mean?
Invex Therapeutics (ASX:IXC) has a Stock Based Compensation of A$0.00 Mil as of Dec. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Invex Therapeutics and its competitors.
Is Invex Therapeutics' Stock Based Compensation too high?
Invex Therapeutics' current Stock Based Compensation is A$0.00 Mil.
How does Invex Therapeutics' Stock Based Compensation compare to VRTX and REGN?
Invex Therapeutics' Stock Based Compensation of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Invex Therapeutics and its competitors. Invex Therapeutics's current Stock Based Compensation is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Stock Based Compensation of A$0.00 Mil. The current Stock Based Compensation is A$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Stock Based Compensation is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.